

Two previously undescribed members of the mouse CPEB family of genes and their inducible expression in the principal cell layers of the hippocampus

Martin Theis^{*†}, Kausik Si[†], and Eric R. Kandel^{**†}

^{*}Howard Hughes Medical Institute and [†]Center for Neurobiology and Behavior, College of Physicians and Surgeons of Columbia University and New York State Psychiatric Institute, New York, NY 10032

Contributed by Eric R. Kandel, June 5, 2003

Cytoplasmic polyadenylation element-binding (CPEB) proteins control polyadenylation-induced translation in early development. Studies in oocytes led to the delineation of *Xenopus* CPEB, the first member of the family to be identified, and its mouse homologue mCPEB-1. Recently, a second mouse family member, mCPEB-2, has been described in germ cells. Increasing evidence also implicates CPEB proteins as being important in the hippocampus, where these proteins are thought to regulate local protein synthesis and synaptic plasticity. We therefore carried out a systematic screen for CPEB genes in the mouse brain and report two previously undescribed gene family members: mCPEB-3 and -4. We next examined the expression of all four genes in the hippocampus and found that mCPEB-1, -2, and -4 transcripts are expressed in the principal cell layer in the CA3 and CA1 region and in the dentate gyrus of the hippocampus. mCPEB-3 was barely expressed in naïve animals but together with mCPEB-4 was strongly up-regulated after injection of kainate to initiate seizure activity. Whereas mCPEB-1 is regulated by the Aurora kinase, mCPEB-2, -3, and -4 do not contain Aurora kinase phosphorylation sites. However, alternative splice isoforms of mCPEB-2, -3, and -4 encode the so-called B region with phosphorylation sites for cAMP-dependent protein kinase, calcium/calmodulin-dependent protein kinase II, and S6 kinase. Only isoforms that encode the B region were expressed in the principal cell layer. Coexpression of mCPEB-1 and the B region-containing splice isoforms suggests that a variety of different signaling pathways can recruit CPEB activity in hippocampal neurons.

Local protein synthesis has long been known to be important for temporal and spatial control of embryonic development (1) and has recently also been shown to be important in synaptic plasticity (2–4). Several transcripts crucial to these changes possess 3' UTRs with polyadenylated tails that can be subject to stimulus-dependent elongation by cytoplasmic polyadenylation (1, 4–8). Transcripts so regulated contain a conserved nucleotide sequence in the 3' UTR: the cytoplasmic polyadenylation element (CPE) with the consensus UUUUUU (1). These sequences are recognized by the CPE-binding protein (CPEB), which aids in the assembly of a protein complex that allows polyadenylation (1). CPEB is not only an activator, however; it is also capable of acting as a repressor of translation. Indeed, under basal conditions, CPEB keeps bound mRNA in a dormant state (1). In the case of CPEB-1, this repression is relieved by phosphorylation (9) or degradation (10) of CPEB. As a result, local signals acting on CPEB contribute to the spatial specificity of CPEB-mediated local protein synthesis (11).

Much of the classical initial work on CPEB-1 was carried out in *Xenopus* oocytes. However, recently CPEB-1 has also been found to be present in the hippocampus (7), where protein synthesis is essential for the late phase of long-term potentiation (L-LTP) (12, 13). In the rodent CNS, activation of Aurora kinase by the *N*-methyl-D-aspartate receptor leads to the phosphorylation of CPEB-1 and the subsequently enhanced cytoplasmic polyadenylation and translation of the transcript encoding the α subunit of the calcium/calmodulin-dependent protein kinase

(CaMKII α) (14), a key element in hippocampal LTP (15, 16). The 3' UTR of CaMKII α transcripts regulates dendritic targeting of the mRNA (17) and contains CPE elements (7). Indeed, mice lacking the CaMKII α 3' UTR show strongly decreased dendritic mRNA localization, a decreased protein content in postsynaptic density fractions, and a deficit in L-LTP (18). However, electrophysiological investigation of mCPEB-1-deficient mice (19) revealed only modest changes in L-LTP (J. M. Alarcon, R. Hodgman, M.T., E.R.K., and J. D. Richter, unpublished data). Because lack of mCPEB-1 may be compensated for by other proteins that mediate local protein synthesis, we were prompted to search for additional CPEB family members expressed in mouse brain. Recently, the murine isoform mCPEB-2 was found in testis (20). In addition, two human brain cDNAs, called KIAA0940 and KIAA1673, have been identified as potentially encoding CPEB proteins (1) with high homology to mCPEB-2 (20).

We have now characterized the expression of mCPEB-2 in the brain. In addition, we have isolated two previously undescribed members (mCPEB-3 and -4) in the mouse and compared their expression pattern in the brain to that of mCPEB-2 and -1. mCPEB-3 and -4 were strongly induced *in vivo* by injection of kainate, a glutamate receptor agonist that leads to strong neuronal activation and seizures (21). Unlike mCPEB-1, the other CPEB isoforms lack Aurora kinase phosphorylation sites. In the so-called B region, whose presence depends on alternative splicing, mCPEB-2, -3, and -4 possess putative phosphorylation sites for cyclic AMP-dependent protein kinase (PKA), CaMKII, and p70S6 kinase, a growth-factor-stimulated serine threonine kinase that acts on components of the translational apparatus (22). In the hippocampus, splice isoforms that possess the B region encoding these phosphorylation sites were enriched in the principal cell layers and might possibly compensate for mCPEB-1 deficiency.

Materials and Methods

Amplification of cDNAs and Generation of Full-Length ORFs. Mouse brain cDNA (Marathon-Ready and QuickClone, CLONTECH; First Choice, Ambion, Austin, TX) was amplified by using the Advantage2 PCR kit (CLONTECH). PCR applications and primer sequences can be found in *Supporting Text*, which is published as supporting information on the PNAS web site, www.pnas.org. For sequence comparisons, the CLUSTALW method and MEGALIGN program (DNASTAR, Madison, WI) were used.

Abbreviations: CPE, cytoplasmic polyadenylation element; CPEB, CPE-binding protein; mCPEB, mouse homologue of CPEB; PKA, cyclic AMP-dependent protein kinase; CaMK, calcium/calmodulin-dependent protein kinase; LTP, long-term potentiation; L-LTP, late-phase LTP.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AY313774 for mCPEB-3 and AY313775 for mCPEB-4).

[†]To whom correspondence should be addressed. E-mail: mt2050@columbia.edu.




Fig. 2. mCPEB-3 and -4 splice isoforms in mouse brain. (A) CPEB proteins contain an N-terminal regulatory domain and a C-terminal RNA-binding domain that consists of two RNA recognition motifs and a Zn-finger domain. (B) Schematic view of mCPEB-3 and relative quantitation of different splice isoforms. (Upper) mCPEB-3 contains a variable region with two amino acid stretches that are lacking in some splice variants. The B stretch (hatched box) contains putative phosphorylation sites (filled circle) and is separated from the C stretch (striated box). (Lower Left) Analysis of brain cDNA subjected to PCR with primers flanking the variable region yields four amplicons differing in size and intensity. Corresponding plasmids containing the different splice isoforms (a–d) are run in parallel. M, 100-base-pair ladder. (Lower Right) Schematic view of the corresponding variant polypeptides. The mCPEB-3a splice isoform is most abundant in brain. (C) Presence of mCPEB-4 isoforms in brain. For explanations, see B. (Upper) Variable region in the N-terminal half. Unlike mCPEB-3, the B stretch is not separated from the C stretch. (Lower Right) PCR with primers flanking the variable region yields four amplicons differing in size and intensity. Corresponding plasmids containing the four mCPEB-4 splice isoforms served as size standards. (Lower Left) Schematic view of the corresponding variant polypeptides. The mCPEB-4a isoform is slightly more abundant in brain.

four different splice isoforms (Figs. 1 and 2C). The longest isoform of mCPEB-4 (called mCPEB-4a) encoded a polypeptide of 729-aa length, whereas the mCPEB-4b isoform had a 24-bp deletion (8 aa, B deletion). The mCPEB-4c isoform was characterized by a large deletion of 51 bp (17 aa, C deletion), and the mCPEB-4d isoform lacked both sequences, i.e., 75 bp (25 aa). The cDNA sequences corresponded to putative exons on mouse chromosome 11 (Ensembl database). Semiquantitative PCR of three different mouse brain cDNAs with primers flanking the alternatively spliced region yielded four amplicons. The mCPEB-4a isoform seemed most abundant (Fig. 2C). Northern blot hybridization revealed the strongest expression of a 6.6-kb mCPEB-4 transcript in brain and in 14.5-day postcoitum embryos; strong expression in kidney, lung, and heart; and weaker expression in liver, spleen, and ovary (Fig. 3B).

Isolation and Expression Analysis of mCPEB-2. mCPEB-2 has recently been isolated from testis. We amplified a fragment of the mCPEB-2 ORF from mouse brain cDNA. The isolated product showed 100% sequence identity to the recently described mCPEB-2 mRNA from testis (20) and the cDNA XM.132072. Both published sequences differed by a 24-bp deletion in testis cDNA. The deletion was homologous to the B deletion of




Fig. 3. Tissue distribution of mouse CPEB transcripts determined by Northern blotting. Tissue array Northern blots were hybridized to probes specific for mCPEB-3 (A), -4 (B), -2 (C), and -1 (D). Transcript sizes are indicated in kilobases. H, heart; B, brain; Li, liver; S, spleen; K, kidney; E, embryo 14.5 days postcoitum; Lu, lung; Th, thymus; Te, testis; O, ovary. (A Inset) Northern blot for human KIAA0940 shows strong expression in skeletal muscle (Right) and weaker expression in heart (Center), and brain (Left), which shows a brain-specific long transcript as observed in mouse.

mCPEB-3 and -4 (Fig. 4B). Using 5' RACE, we extended the sequence information from brain cDNA by 339 bp and always obtained sequences encoding the B region. Another difference compared with the mCPEB-2 mRNA from testis was an extension of several kilobases in the 3' UTR of XM.132072. Using 3' RACE of brain cDNA, we obtained a large 4.5-kb product. The terminal sequences were identical to the 3' end of XM.132072. The calculated length of the 3' UTR was \approx 3.8 kb, longer than the 3' UTR described in the mCPEB-2 mRNA from testis (20). Northern blot hybridization for mCPEB-2 mRNA showed a 2.7-kb fragment in testis (Fig. 3C) that has been described (20). We additionally observed a long 5.5-kb transcript with strongest expression in brain and weaker expression in heart, kidney, embryo, and lung (Fig. 3C). Thus, mCPEB-2 has a short transcript that is very abundantly expressed in testis and a long transcript that is expressed at a lower level in other tissues.

Finally, we determined the tissue distribution of mCPEB-1 mRNA by Northern blotting (Fig. 3D). We found a transcript of \approx 2.6 kb most abundant in brain, which also showed strong expression in kidney, lung, and ovary and weaker expression in heart.

Comparison of the Mouse CPEB Family Members. The mouse mCPEB-3 and -4 isoforms, homologues of human KIAA0940 and KIAA1673, are most similar to mCPEB-2 and show less homology to mCPEB-1 and *Aplysia* CPEB (Fig. 4A). The similarity among the three mouse subfamily members is strongest in the RNA-binding domain (Fig. 4A). We identified a




Fig. 4. Comparison of CPEB family members. (A) Homology percentages of the full-length proteins and of the RNA-binding domains were calculated by using CLUSTALW, respectively, for the mouse and *Aplysia* CPEBs. (B) Sequence comparison of variable regions in mCPEB-2, -3, and -4 proteins. The B region is conditionally present in all mCPEBs. Consensus phosphorylation sites for PKA, CaMKII, and p70S6 kinase are shown above the sequences, and the phosphorylated residue is marked by an asterisk. The corresponding actual recognition sites are shaded. The a and c isoforms of mCPEB-3 and -4 and the mCPEB-2 isoform isolated from brain (mCPEB-2br) possess this site. Note that the phosphorylated serine residue does not reside in the variable region. However, the kinase recognition sites are disrupted by the B deletion. The b and d isoforms of mCPEB-3 and -4 and the testis-specific mCPEB-2 isoform (mCPEB-2t) lack the B region (underlined). Only mCPEB-4 isoforms conditionally lack the C (4) region. Only mCPEB-3 isoforms conditionally lack the C (3) region. +, conserved residues. Similar residues are written in lower case; gaps are underlined.

central region that was characterized by modest sequence homology and interspersed variations, i.e., insertions and deletions (Fig. 4B). All full-length mCPEB proteins contained an 8-aa stretch called the B region with the consensus sequence T/ART/SYGRRR. The region was lacking in mCPEB-2 from testis and

in the b and d isoforms of mCPEB-3 and -4 (Fig. 4B). We analyzed mCPEB polypeptides for the presence of Aurora kinase phosphorylation sites as described (10) and for additional phosphorylation sites by using the web tools NETPHOS 2.0 (www.cbs.dtu.dk/services/NetPhos) and PHOSPHOBASE (www.cbs.dtu.dk/databases/PhosphoBase). In contrast to mCPEB-1, which has Aurora kinase phosphorylation sites, the deduced mCPEB-2, -3, and -4 polypeptides did not contain Aurora kinase phosphorylation sites. However, for all those mCPEBs, we found a site within the B variable region (Fig. 4B) that provides consensus recognition sites for phosphorylation by PKA and CaMKII (R-X-X-S/T-X; refs. 24 and 25) and p70S6 kinase (K/R-X-R-X-X-S/T-X; ref. 26). These sites allow phosphorylation of a serine residue adjacent to the B region exclusively in a and c isoforms of mCPEB-3, -4, and -2 from brain. However, those recognition sites are not universal and are absent in b and d isoforms of mCPEB-3, -4, and -2 from testis (Fig. 4B).

Cell-Type Specificity in Brain. We determined mCPEB-2, -3, and -4 expression by *in situ* hybridization of mouse brain and compared their expression pattern with mCPEB-1 (Fig. 5A1). Whereas mCPEB-4 (Fig. 5D1) showed a higher basal expression level compared with mCPEB-1 in the principal cells of the hippocampal formation, mCPEB-3 was barely detectable (Fig. 5C1). mCPEB-2 showed expression in principal cells of the hippocampus (Fig. 5B1) with intensity and distribution similar to mCPEB-1.

With the exception of mCPEB-4, the expression levels of the mCPEBs, as determined by *in situ* hybridization, were low in the normal mouse brain. We therefore tested whether mCPEBs were induced by strong neuronal stimulation, injected kainate i.p., and analyzed brains at different time points after induction compared with noninjected control animals. As a positive control, we used Arc, an mRNA known to be induced by electrical induction of seizures (27). Arc mRNA was hardly detectable in the basal state but strongly up-regulated 1, 2, 4, and 8 h after kainate stimulation (not shown). mCPEB-3 was barely detectable in the basal state (Fig. 5C1) and 1 h postinjection (Table 1) but was




Fig. 5. mCPEB transcript distribution in mouse hippocampus under basic conditions and after kainate induction. Coronal cryosections were hybridized with oligonucleotides specific for mCPEB isoforms. (A1–A3) mCPEB-1. (B1–B3) mCPEB-2. (C1–C3) mCPEB-3. (D1–D3) mCPEB-4. Expression of mCPEB isoforms is shown under basic conditions (A1, B1, C1, and D1), 2 h after kainate induction (A2, B2, C2, and D2), and 4 h after kainate induction (A3, B3, C3, and D3). Exposition was 3 days for mCPEB-3 and -4 probes and 4 wk for mCPEB-1 and -2 probes. Except for mCPEB-2, two probes were used for each transcript, yielding qualitatively identical results.

Table 1. Relative mCPEB transcript abundance in the principal cell layers of the hippocampus at different time points after kainate injection

Hours	CPEB-1	CPEB-2	CPEB-3	CPEB-4
CA3/1				
0	+	+	-	++
1	+	+	-	++
2	+	+	+++	++
4	+	+	+++	+++
8	+	+	+	++
DG				
0	+	+	-	++
1	+	+	-	++++
2	+	+	+++	++++
4	+	+	-	++(+)
8	+	+	-	++

Staining is graded as barely detectable (-), low (+), moderate (++), strong (+++), and very strong (++++). DG, dentate gyrus.

strongly expressed in the principal cells of the cornu ammonis and dentate gyrus 2 h after injection (Fig. 5C2). The expression of mCPEB-3 in dentate gyrus was decreased to basal levels 4 h postinjection in four of six animals but remained stable in CA3 and CA1 (Fig. 5C3). Eight hours later, expression decreased but remained elevated in CA1/CA3, albeit at lower levels than at 4 and 2 h (Table 1). In parallel, mCPEB-4 was up-regulated 1 h (Table 1) and 2 h after injection in granule cells of the dentate gyrus (Fig. 5D2) and was decreased to levels slightly above basal levels in dentate gyrus 4 h after stimulation (Fig. 5D3). In CA3 and CA1, up-regulation was apparent 4 h after stimulation (Fig. 5D3). After 8 h, expression reached basal levels (Table 1). In contrast, mCPEB-1 levels did not change at all during stimulation (Fig. 5A1–3) and were low compared with the basal level of mCPEB-4 (Fig. 5D1) and the induced mCPEB-3 levels (Fig. 5C2 and C3). Similarly, mCPEB-2 was not influenced by kainic acid (Fig. 5B1–3).

To determine the isoform specificity of mCPEB expression in the principal cell layers of the hippocampus, we used oligonucleotides complementary to DNA sequences flanking the individual splice sites of mCPEB-3 and -4. For mCPEB-3, it was not possible to derive oligonucleotides exclusively directed to individual isoforms, because the C and B exons are separated by an exon that is contained in all mCPEB-3 isoforms. Starting 2 h after induction, we found expression in principal cells by using an oligonucleotide directed to both the mCPEB-3a and -3c isoforms that contain the B region (Fig. 6A) but not with another oligonucleotide directed to both the mCPEB-3b and -3d isoforms that lack the B region (Fig. 6B). For mCPEB-4, we obtained labeling of the principal cell layers of the hippocampus 1 h after induction by using an oligonucleotide specific for mCPEB-4a (Fig. 6C) and weak labeling with an oligonucleotide specific for mCPEB-4d (Fig. 6E). The two isoforms that lack the B exon encoding the putative phosphorylation sites (mCPEB-4b and -4d) were not detected in the principal cell layers either in naïve animals or after induction (Figs. 6D and F).

Discussion

The modest changes in the synaptic physiology in mCPEB-1-deficient mice (J. M. Alarcon, R. Hodgman, M.T., E.R.K., and J. D. Richter, unpublished data) and the recent observation in *Aplysia* that there might be neuron-specific isoforms of CPEB (5) prompted us to carry out a systematic search for new CPEB family members in mice that might be present in brain. We now have identified two putative mouse CPEB isoforms, which we call mCPEB-3 and -4. These two differ from mCPEB-1 both in




Fig. 6. Isoform distribution of mCPEB-3 and -4 in principal cell layers of the hippocampus. (A) mCPEB-3a/c-specific probe, 2 h after kainate induction. (B) mCPEB-3b/d-specific probe (2 h). (C) mCPEB-4a-specific probe (1 h). (D) mCPEB-4b-specific probe (1 h). (E) mCPEB-4c-specific probe (1 h). (F) mCPEB-4d-specific probe (1 h).

their patterns of expression and in their regulatory features. This raises the possibility that the different family members of CPEB might regulate different aspects of the temporal and spatial order of local protein synthesis.

Mouse CPEB Family Members Have Distinct Neuronal Expression Patterns.

We found that all four CPEB genes are expressed in granular cells of dentate gyrus and the pyramidal cells of CA3 and CA1. However, unlike mCPEB-1 and -2, the isoforms mCPEB-3 and -4 were up-regulated by strong neuronal activation. Interestingly, the up-regulation of mCPEB-3 and -4 is transient in the dentate gyrus but more long lasting in the CA3 and CA1 region. Their spatiotemporal kinetics are intriguing because they follow the principal path of the information flow in the hippocampus (28). The complexity of expression pattern is further accentuated by the differential distribution of various splice isoforms.

The mouse mCPEB-3 protein is particularly interesting, because it seems a likely candidate for being the functional homologue of the *Aplysia* neuronal CPEB. mCPEB-3 shares three common features with *Aplysia* CPEB. First, in the N-terminal domain, both possess a glutamine-rich region (ref. 5; Fig. 1). Second, neither of them contains Aurora kinase phosphorylation sites. Finally, the expression of both *Aplysia* CPEB and mouse mCPEB-3 is up-regulated after neuronal stimulation: for *Aplysia* CPEB, regulation occurs posttranscriptionally (ref. 5; K.S., M. Giustetto, A. Etkin, R. Hsu, H. Zhu, and E.R.K., unpublished data), whereas mCPEB-3 is up-regulated at the transcriptional level (Fig. 5). A conceivable late activity of mCPEB-3 protein supporting expression of L-LTP or its maintenance would be consistent with the observed late induction of mCPEB-3.

Mouse CPEB Family Members Might Be Regulated by Distinct Signaling Pathways.

What controls the activity of different mouse CPEB family members? In the case of mCPEB-1, stimulation of hippocampal cells by glutamate leads to the *N*-methyl-D-aspartate-receptor-dependent activation of Aurora kinase, which in turn phosphorylates mCPEB-1 (14). In contrast to mCPEB-1, the other mouse CPEB family members do not contain Aurora kinase phosphorylation sites. Instead, all of them

have splice variants that are selectively expressed in the principal cell layers and contain the putative recognition sites for PKA, CaMKII, and S6 kinase. Interestingly, S6 kinase is a downstream effector of FRAP/mTOR kinase pathway (22), a pathway that has already been implicated in L-LTP (29). An inhibitor of FRAP/mTOR, rapamycin, blocks the late phase of LTF in *Aplysia* and L-LTP in the mouse (2, 29). CPEB activity might also be regulated by PKA (5) or CaMKII phosphorylation. In addition, mCPEBs might control their expression by an autoregulatory feedback loop: RACE experiments for mCPEB-3 yielded two different transcripts, both of which contain putative CPEs near polyadenylation signals. The *Aplysia* homologue of mCPEB-3 also contains CPEs in its 3' UTR (K.S., M. Giustetto, A. Etkin, R. Hsu, H. Zhu, and E.R.K., unpublished data). This raises the possibility that activation of mCPEB-1 after *N*-methyl-D-aspartate receptor activation (7, 14) can in turn result in the activation of mCPEB-3. The autoregulatory loop of CPEB activation has already been demonstrated in *Drosophila* (30).

Different mCPEB Molecules Might Be Involved in Different Phases or Forms of Synaptic Plasticity. Why are there so many mCPEB molecules, and what specific role do they play in long-term synaptic plasticity? That mCPEB1, -2, and -4 are present in the basal state and mCPEB-3 and -4 are induced sequentially may reflect a differential temporal requirement of mCPEBs. Alter-

natively, different mCPEBs might be involved as well in distinct forms of synaptic plasticity or in nonplastic functions. A clue to such possibility came from the analysis of LTP in mCPEB-1-deficient mice: LTP induced by the neurotrophin brain-derived neurotrophic factor (BDNF) was completely unaffected by the absence of mCPEB-1 (J. M. Alarcon, R. Hodgman, M.T., E.R.K., and J. Richter, unpublished data), even though BDNF-mediated LTP requires local protein synthesis (29). What might be controlling the local synaptic protein synthesis in BDNF-dependent LTP? Because rapamycin completely abrogates BDNF-mediated LTP (29) and mCPEB-2, -3, and -4 contain a putative S6 kinase site, one can imagine part of this rapamycin-sensitive translational activation can be mediated by mCPEB-3 and -4. Indeed the induction of the *Aplysia* homologue of mCPEB-3 is blocked by rapamycin (K.S., M. Giustetto, A. Etkin, R. Hsu, H. Zhu, and E.R.K., unpublished data). Finally, different mCPEB family members might have distinct substrate specificities.

Note Added in Proof. For the human CPEB gene family, a nomenclature has been proposed (10) that differs from the nomenclature for the mouse CPEB gene family (20).

We thank James Schwartz for critical comments. This work was supported by the Howard Hughes Medical Institute.

- Mendez, R. & Richter, J. D. (2001) *Nat. Rev. Mol. Cell Biol.* **2**, 521–529.
- Casadio, A., Martin, K. C., Giustetto, M., Zhu, H., Chen, M., Bartsch, D., Bailey, C. H. & Kandel, E. R. (1999) *Cell* **99**, 221–237.
- Martin, K. C., Barad, M. & Kandel, E. R. (2000) *Curr. Opin. Neurobiol.* **10**, 587–592.
- Steward, O. & Schuman, E. M. (2001) *Annu. Rev. Neurosci.* **24**, 299–325.
- Liu, J. & Schwartz, J. H. (2003) *Brain Res.* **959**, 68–76.
- Wells, D. G., Dong, X., Quinlan, E. M., Huang, Y. S., Bear, M. F., Richter, J. D. & Fallon, J. R. (2001) *J. Neurosci.* **21**, 9541–9548.
- Wu, L., Wells, D., Tay, J., Mendis, D., Abbott, M. A., Barnitt, A., Quinlan, E., Heynen, A., Fallon, J. R. & Richter, J. D. (1998) *Neuron* **21**, 1129–1139.
- Minshall, N., Walker, J., Dale, M. & Standart, N. (1999) *RNA* **5**, 27–38.
- Mendez, R., Hake, L. E., Andresson, T., Littlepage, L. E., Ruderman, J. V. & Richter, J. D. (2000) *Nature* **404**, 302–307.
- Mendez, R., Barnard, D. & Richter, J. D. (2002) *EMBO J.* **21**, 1833–1844.
- Richter, J. D. & Lorenz, L. J. (2002) *Curr. Opin. Neurobiol.* **12**, 300–304.
- Frey, U., Krug, M., Reymann, K. G. & Matthies, H. (1988) *Brain Res.* **452**, 57–65.
- Nguyen, P. V., Abel, T. & Kandel, E. R. (1994) *Science* **265**, 1104–1107.
- Huang, Y. S., Jung, M. Y., Sarkissian, M. & Richter, J. D. (2002) *EMBO J.* **21**, 2139–2148.
- Miyamoto, E. & Fukunaga, K. (1996) *Neurosci. Res.* **24**, 117–122.
- Silva, A. J., Stevens, C. F., Tonegawa, S. & Wang, Y. (1992) *Science* **257**, 201–206.
- Mayford, M., Baranes, D., Podsypanina, K. & Kandel, E. R. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 13250–13255.
- Miller, S., Yasuda, M., Coats, J. K., Jones, Y., Martone, M. E. & Mayford, M. (2002) *Neuron* **36**, 507–519.
- Tay, J. & Richter, J. D. (2001) *Dev. Cell* **1**, 201–213.
- Kurihara, Y., Tokuriki, M., Myojin, R., Hori, T., Kuroiwa, A., Matsuda, Y., Sakurai, T., Kimura, M., Hecht, N. B. & Uesugi, S. (2003) *Biol. Reprod.* **69**, 261–268.
- Zagulska-Szymczak, S., Filipkowski, R. K. & Kaczmarek, L. (2001) *Neurochem. Int.* **38**, 485–501.
- Gingras, A. C., Raught, B. & Sonenberg, N. (2001) *Genes Dev.* **15**, 807–826.
- Wisden, W. & Morris, B. J. (1994) in *In Situ Hybridization Protocols for the Brain*, eds. Wisden, W. & Morris, B. J. (Academic, San Diego), pp. 9–34.
- Kennelly, P. J. & Krebs, E. G. (1991) *J. Biol. Chem.* **266**, 15555–15558.
- Kemp, B. E. & Pearson, R. B. (1990) *Trends Biochem. Sci.* **15**, 342–346.
- Pinna, L. A. & Ruzzene, M. (1996) *Biochim. Biophys. Acta* **1314**, 191–225.
- French, P. J., O'Connor, V., Jones, M. W., Davis, S., Errington, M. L., Voss, K., Truchet, B., Wotjak, C., Stean, T., Doyere, V., et al. (2001) *Eur. J. Neurosci.* **13**, 968–976.
- Bliss, T. V. & Lomo, T. (1973) *J. Physiol.* **232**, 331–356.
- Tang, S. J., Reis, G., Kang, H., Gingras, A. C., Sonenberg, N. & Schuman, E. M. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 467–472.
- Tan, L., Chang, J. S., Costa, A. & Schedl, P. (2001) *Development (Cambridge, U.K.)* **128**, 1159–1169.